Cureline, Inc. – Trademark Portfolio
Entity Type: 03
Cureline, Inc. holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 7 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 3 Nice Classification classes. Currently, 7 trademarks are registered. Notable registered marks include CURELINE, TISSUE 2 TARGET, CURELINE TRANSLATIONAL CRO, CURELINE MOLECULAR SERVICES, and CURELINE HUMAN BIOSPECIMEN CRO. The owner is based in Brisbane, CA.
Suite 24
150 N. Hill Dr.
Brisbane, CA 94005
Showing of trademarks Trademarks
Trademark Classifications
Cureline, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Cureline, Inc. have?
Cureline, Inc. has 7 U.S. trademarks filed with the USPTO. Of these, 7 registered.
What trademark classes does Cureline, Inc. file in?
Cureline, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 1 (Chemicals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Cureline, Inc.'s most well-known trademarks?
Cureline, Inc.'s registered trademark portfolio includes well-known marks such as CURELINE, TISSUE 2 TARGET, CURELINE TRANSLATIONAL CRO, CURELINE MOLECULAR SERVICES, and CURELINE HUMAN BIOSPECIMEN CRO. These are among 7 currently registered trademarks in the portfolio.
What is Cureline, Inc.'s trademark registration success rate?
Cureline, Inc. has a 100% trademark registration rate, with 7 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.